Novartis Corporation (NVS) (JOBS) To Pay Corthera Up To $620M For Heart Drug Rights
12/23/2009 6:58:51 AM
More...
|
Corthera's Relaxin Receives FDA Fast Track Designation for the Treatment of Acute Heart Failure
10/1/2009 10:44:51 AM
More...
|
Results and Additional Analyses From Study Show That Corthera's Relaxin for Acute Heart Failure is the Strongest Predictor of Improved Longer-Term Outcomes Following Hospital Discharge When Compared to Other Variables
6/1/2009 8:35:43 AM
More...
|
Results and Additional Analyses From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
5/28/2009 11:20:18 AM
More...
|
Corthera Release: Results From Study Show Promising Efficacy and Safety Results for Corthera's Relaxin in Acute Heart Failure
3/30/2009 8:20:12 AM
More...
|
Results From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at American College of Cardiology
3/23/2009 11:19:10 AM
More...
|
Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Corthera's Relaxin in Acute Heart Failure
11/10/2008 8:52:50 AM
More...
|
Corthera Top-Line Preliminary Data From Phase II/III Study of Corthera's Relaxin in Acute Heart Failure to be Presented in Satellite Symposium at American Heart Association Scientific Sessions 2008
11/3/2008 7:48:20 AM
More...
|
University of Cincinnati First in US to Study Corthera's Relaxin for Heart Failure
7/8/2008 2:47:09 PM
More...
|
Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure
1/8/2008 8:00:52 AM
More...
|
|